In normal settings, increased HDAC2 level should decrease the acetylation of PARP-1, but amongst COPD patients, the increase in PARP-1 can be so significant that the balance between normal HDAC2 and PARP-1 is markedly shifted. The gene discussed is PARP1; the disease is chronic obstructive pulmonary disease.